Industries > Pharma > Neurological Disorder Drugs Market Report 2021-2031
Neurological Disorder Drugs Market Report 2021-2031
By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antiepileptic, Antipsychotic, Antidepressant, Anticholinergic, Analgesic, Hypnotic & Sedative, Antihypertensive, Anticoagulants, and Others), By Disease Type (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, and Others), By Route of Administration (Parenteral, and Oral), By Drug Type (Generic Drug, and Branded Drug) By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, Academic and Research Institute, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis
Neurological Disorder Drugs Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Neurological Disorder Drugs is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 180+ page report provides 480+ tables and 490+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Neurological Disorder Drugs Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Neurological Disorder Drugs Market By Drug Class
• Cholinesterase Inhibitors
• NMDA Receptor Antagonists
• Antiepileptic
• Antipsychotic
• Antidepressant
• Anticholinergic
• Analgesic
• Hypnotic & Sedative
• Antihypertensive
• Anticoagulants
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Neurological Disorder Drugs Market By Disease Type
• Epilepsy
• Alzheimer’s Disease
• Parkinson’s Disease
• Multiple Sclerosis
• Cerebrovascular Disease
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Neurological Disorder Drugs Market By Route of Administration
• Parenteral
• Oral
• Revenue and growth forecasts from 2021 to 2031 for the Global Neurological Disorder Drugs Market By Drug Type
• Generic Drug
• Branded Drug
• Revenue and growth forecasts from 2021 to 2031 for the Global Neurological Disorder Drugs Market By Patient Demographics
• Geriatric Patient
• Adult Patient
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Neurological Disorder Drugs Market By End User
• Hospitals
• Homecare
• Specialty Clinics
• Academic and Research Institute
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Neurological Disorder Drugs Market By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Neurological Disorder Drugs Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Neurological Disorder Drugs Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Neurological Disorder Drugs Market report helps you
In summary, our 180+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Neurological Disorder Drugs Market, with forecasts for Get our report today Neurological Disorder Drugs Market Forecast 2021-2031: By Drug Class, Disease Type, Route of Administration, Drug Type Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Neurological Disorder Drugs market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Neurological Disorder Drugs Market. Some of the company’s profiled in this report include
• Pfizer Inc
• Eli Lilly and Company
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Eisai Co., Ltd
• Allergan
• Teva Pharmaceutical Industries Ltd
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Endo International plc
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Neurological Disorder Drugs Market and leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Neurological Disorder Drugs Market Report 2021-2031: By Drug Class (Cholinesterase Inhibitors, NMDA Receptor Antagonists, Antiepileptic, Antipsychotic, Antidepressant, Anticholinergic, Analgesic, Hypnotic & Sedative, Antihypertensive, Anticoagulants, and Others), By Disease Type (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, and Others), By Route of Administration (Parenteral, and Oral), By Drug Type (Generic Drug, and Branded Drug) By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, Academic and Research Institute, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Leading Regional/ Country market analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Neurological Disorder Drugs Market
2.1. Neurological Disorder Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Neurological Disorder Drugs Market Overview
3.1. Global Neurological Disorder Drugs Market Size and Forecast By Region
3.2. Global Neurological Disorder Drugs Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of neurological disorder
3.3.1.2. Increasing research and development for neurological disorder drugs
3.3.1.3. Rising awareness regarding treatment of neurological disorder
3.3.1.4. Increasing strategic initiatives in neurological disorder drugs market
3.3.2. Market Restraints
3.3.2.1. High cost of development
3.3.2.2. Unmet medical needs
3.3.2.3. Stringent regulation
3.3.3. Opportunities
3.3.3.1. Increasing focus on healthcare infrastructure and advance therapeutic delivery
3.3.3.2. Increasing strategic initiatives in neurological disorder drugs
3.3.4. Challenges
3.3.4.1. Availability of alternative methods
3.3.4.2. Changes in export & import in the policies
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Neurological Disorder Drugs Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Antihypertensive
4.1.1.1. Antihypertensive market size and forecast, 2021-2031 (USD Million)
4.1.2. NMDA Receptor Antagonists
4.1.2.1. NMDA Receptor Antagonists market size and forecast, 2021-2031 (USD Million)
4.1.3. Antipsychotic
4.1.3.1. Antipsychotic market size and forecast, 2021-2031 (USD Million)
4.1.4. Antidepressant
4.1.4.1. Antidepressant market size and forecast, 2021-2031 (USD Million)
4.1.5. Anticholinergic
4.1.5.1. Anticholinergic market size and forecast, 2021-2031 (USD Million)
4.1.6. Analgesic
4.1.6.1. Analgesic market size and forecast, 2021-2031 (USD Million)
4.1.7. Hypnotic & Sedative
4.1.7.1. Hypnotic & Sedative market size and forecast, 2021-2031 (USD Million)
4.1.8. Antihypertensive
4.1.8.1. Antihypertensive market size and forecast, 2021-2031 (USD Million)
4.1.9. Anticoagulants
4.1.9.1. Anticoagulants market size and forecast, 2021-2031 (USD Million)
4.1.10. Others
4.1.10.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Disease Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Epilepsy
5.1.1.1. Epilepsy market size and forecast, 2021-2031 (USD Million)
5.1.2. Alzheimer’s Disease
5.1.2.1. Alzheimer’s Disease market size and forecast, 2021-2031 (USD Million)
5.1.3. Parkinson’s Disease
5.1.3.1. Parkinson’s Disease market size and forecast, 2021-2031 (USD Million)
5.1.4. Multiple Sclerosis
5.1.4.1. Multiple Sclerosis market size and forecast, 2021-2031 (USD Million)
5.1.5. Cerebrovascular Disease
5.1.5.1. Cerebrovascular Disease market size and forecast, 2021-2031 (USD Million)
5.1.6. Others
5.1.6.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric Patient
6.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult Patient
6.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Oral
8.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
8.1.2. Parenteral
8.1.2.1. Parenteral market size and forecast, 2021-2031 (USD Million)
9. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Homecare
9.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
9.1.3. Academic and Research Institute
9.1.3.1. Academic and Research Institute market size and forecast, 2021-2031 (USD Million)
9.1.4. Specialty Clinics
9.1.4.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.5. Others
9.1.5.1. Others Market size and forecast, 2021-2031 (USD Million)
10. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals Pharmacy
10.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Pharmacy
10.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.3. Online Pharmacies
10.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
11. North America Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Neurological Disorder Drugs Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Neurological Disorder Drugs Market Size and Forecast By Disease Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Neurological Disorder Drugs Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Neurological Disorder Drugs Market Size and Forecast By Route of Administration
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Neurological Disorder Drugs Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Neurological Disorder Drugs Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Neurological Disorder Drugs Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Neurological Disorder Drugs Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Neurological Disorder Drugs Market Size and Forecast By Disease Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Neurological Disorder Drugs Market Size and Forecast By Drug Type
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Neurological Disorder Drugs Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Neurological Disorder Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Neurological Disorder Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Neurological Disorder Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Neurological Disorder Drugs Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Neurological Disorder Drugs Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Disease Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Drug Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Neurological Disorder Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Neurological Disorder Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Neurological Disorder Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Neurological Disorder Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Neurological Disorder Drugs Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Neurological Disorder Drugs Market Size and Forecast By Disease Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Neurological Disorder Drugs Market Size and Forecast By Drug Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Neurological Disorder Drugs Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Neurological Disorder Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
14.9. Brazil Neurological Disorder Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Neurological Disorder Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Neurological Disorder Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Neurological Disorder Drugs Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Neurological Disorder Drugs Market Size and Forecast By Disease Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Neurological Disorder Drugs Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Neurological Disorder Drugs Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Neurological Disorder Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Neurological Disorder Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Neurological Disorder Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Neurological Disorder Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Neurological Disorder Drugs Market
16.1. Pfizer Inc
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. Eli Lilly and Company
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Novartis AG
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. F. Hoffmann-La Roche Ltd
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. Eisai Co., Ltd
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. Allergan
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Teva Pharmaceutical Industries Ltd
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. Bristol-Myers Squibb Company
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Takeda Pharmaceutical Company Limited
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Endo International plc
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Neurological Disorder Drugs Market Drivers & Restraints 2021
Table 7. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 178. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 193. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 248. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 263. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 264. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 265. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 266. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 267. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 268. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 269. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 270. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 271. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 272. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 273. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 274. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 275. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 276. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 277. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 278. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 452. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 453. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 454. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 455. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 456. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 457. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 458. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 459. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 460. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 461. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 462. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 463. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 464. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 465. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 466. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 467. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 468. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 469. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 470. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 471. Leading 10 Neurological Disorder Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 472. Pfizer IncProfile 2019 (CEO, HQ, Founded, Website)
Table 473. Pfizer Inc Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 474. Eli Lilly and Company Profile 2019 (CEO, HQ, Founded, Website)
Table 475. Eli Lilly and Company Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 476. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Novartis AG.Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 478. F. Hoffmann-La Roche Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 479. F. Hoffmann-La Roche Ltd Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 480. Eisai Co., Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 481. Eisai Co., Ltd Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 482. Allergan Profile 2019 (CEO, HQ, Founded, Website)
Table 483. Allergan Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 484. Teva Pharmaceutical Industries Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 485. Teva Pharmaceutical Industries Ltd Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 486. Bristol-Myers Squibb Company Profile 2019 (CEO, HQ, Founded, Website)
Table 487. Bristol-Myers Squibb Company Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 488. Takeda Pharmaceutical Company Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 489. Takeda Pharmaceutical Company Limited Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 490. Endo International plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 491. Endo International plc Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 492. Other Companies Involved in the Neurological Disorder Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Neurological Disorder Drugs Market Drivers & Restraints 2021
Figure 7. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 178. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 193. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 248. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 263. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 264. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 265. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 266. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 267. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 268. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 269. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 270. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 271. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 272. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 273. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 274. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 275. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 276. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 277. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 278. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 279. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 280. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 281. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 282. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 452. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 453. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 454. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 455. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 456. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 457. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 458. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 459. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 460. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 461. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 462. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 463. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 464. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 465. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 466. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 467. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 468. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 469. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 470. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 471. Porter’s Five Force Analysis
Companies Mentioned
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Neurological Disorder Drugs Market
2.1. Neurological Disorder Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Condition Submarkets Definitions
3. Neurological Disorder Drugs Market Overview
3.1. Global Neurological Disorder Drugs Market Size and Forecast By Region
3.2. Global Neurological Disorder Drugs Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of neurological disorder
3.3.1.2. Increasing research and development for neurological disorder drugs
3.3.1.3. Rising awareness regarding treatment of neurological disorder
3.3.1.4. Increasing strategic initiatives in neurological disorder drugs market
3.3.2. Market Restraints
3.3.2.1. High cost of development
3.3.2.2. Unmet medical needs
3.3.2.3. Stringent regulation
3.3.3. Opportunities
3.3.3.1. Increasing focus on healthcare infrastructure and advance therapeutic delivery
3.3.3.2. Increasing strategic initiatives in neurological disorder drugs
3.3.4. Challenges
3.3.4.1. Availability of alternative methods
3.3.4.2. Changes in export & import in the policies
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Neurological Disorder Drugs Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Antihypertensive
4.1.1.1. Antihypertensive market size and forecast, 2021-2031 (USD Million)
4.1.2. NMDA Receptor Antagonists
4.1.2.1. NMDA Receptor Antagonists market size and forecast, 2021-2031 (USD Million)
4.1.3. Antipsychotic
4.1.3.1. Antipsychotic market size and forecast, 2021-2031 (USD Million)
4.1.4. Antidepressant
4.1.4.1. Antidepressant market size and forecast, 2021-2031 (USD Million)
4.1.5. Anticholinergic
4.1.5.1. Anticholinergic market size and forecast, 2021-2031 (USD Million)
4.1.6. Analgesic
4.1.6.1. Analgesic market size and forecast, 2021-2031 (USD Million)
4.1.7. Hypnotic & Sedative
4.1.7.1. Hypnotic & Sedative market size and forecast, 2021-2031 (USD Million)
4.1.8. Antihypertensive
4.1.8.1. Antihypertensive market size and forecast, 2021-2031 (USD Million)
4.1.9. Anticoagulants
4.1.9.1. Anticoagulants market size and forecast, 2021-2031 (USD Million)
4.1.10. Others
4.1.10.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Disease Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Epilepsy
5.1.1.1. Epilepsy market size and forecast, 2021-2031 (USD Million)
5.1.2. Alzheimer’s Disease
5.1.2.1. Alzheimer’s Disease market size and forecast, 2021-2031 (USD Million)
5.1.3. Parkinson’s Disease
5.1.3.1. Parkinson’s Disease market size and forecast, 2021-2031 (USD Million)
5.1.4. Multiple Sclerosis
5.1.4.1. Multiple Sclerosis market size and forecast, 2021-2031 (USD Million)
5.1.5. Cerebrovascular Disease
5.1.5.1. Cerebrovascular Disease market size and forecast, 2021-2031 (USD Million)
5.1.6. Others
5.1.6.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Geriatric Patient
6.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
6.1.2. Adult Patient
6.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
6.1.3. Pediatric
6.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
7. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Generic Drugs
7.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
7.1.2. Branded Drugs
7.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
8. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Oral
8.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
8.1.2. Parenteral
8.1.2.1. Parenteral market size and forecast, 2021-2031 (USD Million)
9. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospitals
9.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
9.1.2. Homecare
9.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
9.1.3. Academic and Research Institute
9.1.3.1. Academic and Research Institute market size and forecast, 2021-2031 (USD Million)
9.1.4. Specialty Clinics
9.1.4.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
9.1.5. Others
9.1.5.1. Others Market size and forecast, 2021-2031 (USD Million)
10. Global Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals Pharmacy
10.1.1.1. Hospitals Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.2. Retail Pharmacy
10.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
10.1.3. Online Pharmacies
10.1.3.1. Online Pharmacies market size and forecast, 2021-2031 (USD Million)
11. North America Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. North America Neurological Disorder Drugs Market Size and Forecast By Drug Class
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. North America Neurological Disorder Drugs Market Size and Forecast By Disease Type
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. North America Neurological Disorder Drugs Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. North America Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. North America Neurological Disorder Drugs Market Size and Forecast By Route of Administration
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. North America Neurological Disorder Drugs Market Size and Forecast By End-User
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. North America Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. U.S. Neurological Disorder Drugs Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. Canada Neurological Disorder Drugs Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
12. Europe Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Europe Neurological Disorder Drugs Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Europe Neurological Disorder Drugs Market Size and Forecast By Disease Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Europe Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Europe Neurological Disorder Drugs Market Size and Forecast By Drug Type
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Europe Neurological Disorder Drugs Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Europe Neurological Disorder Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. Europe Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. UK Neurological Disorder Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Germany Neurological Disorder Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. France Neurological Disorder Drugs Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
12.12. Rest of Europe Neurological Disorder Drugs Market
12.12.1.1. XX Driving/Opportunity Factor
12.12.1.2. XX Driving/Opportunity Factor
13. Asia Pacific Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Disease Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Drug Type
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Asia-Pacific Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. China Neurological Disorder Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. India Neurological Disorder Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. Japan Neurological Disorder Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Asia Pacific Neurological Disorder Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Latin America Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Latin America Neurological Disorder Drugs Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Latin America Neurological Disorder Drugs Market Size and Forecast By Disease Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Latin America Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Latin America Neurological Disorder Drugs Market Size and Forecast By Drug Type
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Latin America Neurological Disorder Drugs Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Latin America Neurological Disorder Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Latin America Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
14.9. Brazil Neurological Disorder Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Mexico Neurological Disorder Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Rest of Latin America Neurological Disorder Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
15. MEA Neurological Disorder Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. MEA Neurological Disorder Drugs Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. MEA Neurological Disorder Drugs Market Size and Forecast By Disease Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. MEA Neurological Disorder Drugs Market Size and Forecast By Patient Demographics
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. MEA Neurological Disorder Drugs Market Size and Forecast By Drug Type
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. MEA Neurological Disorder Drugs Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. MEA Neurological Disorder Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. MEA Neurological Disorder Drugs Market Size and Forecast By Distribution Channel
15.8.1.1. XX Driving/Opportunity Factor
15.8.1.2. XX Driving/Opportunity Factor
15.9. GCC Neurological Disorder Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. South Africa Neurological Disorder Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of MEA Neurological Disorder Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. Companies in the Neurological Disorder Drugs Market
16.1. Pfizer Inc
16.1.1. Company Snapshot
16.1.2. Company Overview
16.1.3. Financial Performance (2015-2019)
16.1.3.1. Net Revenue
16.1.3.2. Gross Profit
16.1.3.3. Geographical Revenue, 2019
16.1.4. Product Offerings
16.1.5. Recent Initiatives (2017-2019)
16.2. Eli Lilly and Company
16.2.1. Company Snapshot
16.2.2. Company Overview
16.2.3. Financial Performance (2015-2019)
16.2.3.1. Net Revenue
16.2.3.2. Gross Profit
16.2.3.3. Geographical Revenue, 2019
16.2.4. Product Offerings
16.2.5. Recent Initiatives (2017-2019)
16.3. Novartis AG
16.3.1. Company Snapshot
16.3.2. Company Overview
16.3.3. Financial Performance (2015-2019)
16.3.3.1. Net Revenue
16.3.3.2. Gross Profit
16.3.3.3. Geographical Revenue, 2019
16.3.4. Product Offerings
16.3.5. Recent Initiatives (2017-2019)
16.4. F. Hoffmann-La Roche Ltd
16.4.1. Company Snapshot
16.4.2. Company Overview
16.4.3. Financial Performance (2015-2019)
16.4.3.1. Net Revenue
16.4.3.2. Gross Profit
16.4.3.3. Geographical Revenue, 2019
16.4.4. Product Offerings
16.4.5. Recent Initiatives (2017-2019)
16.5. Eisai Co., Ltd
16.5.1. Company Snapshot
16.5.2. Company Overview
16.5.3. Financial Performance (2015-2019)
16.5.3.1. Net Revenue
16.5.3.2. Gross Profit
16.5.3.3. Geographical Revenue, 2019
16.5.4. Product Offerings
16.5.5. Recent Initiatives (2017-2019)
16.6. Allergan
16.6.1. Company Snapshot
16.6.2. Company Overview
16.6.3. Financial Performance (2015-2019)
16.6.3.1. Net Revenue
16.6.3.2. Gross Profit
16.6.3.3. Geographical Revenue, 2019
16.6.4. Product Offerings
16.6.5. Recent Initiatives (2017-2019)
16.7. Teva Pharmaceutical Industries Ltd
16.7.1. Company Snapshot
16.7.2. Company Overview
16.7.3. Financial Performance (2015-2019)
16.7.3.1. Net Revenue
16.7.3.2. Gross Profit
16.7.3.3. Geographical Revenue, 2019
16.7.4. Product Offerings
16.7.5. Recent Initiatives (2017-2019)
16.8. Bristol-Myers Squibb Company
16.8.1. Company Snapshot
16.8.2. Company Overview
16.8.3. Financial Performance (2015-2019)
16.8.3.1. Net Revenue
16.8.3.2. Gross Profit
16.8.3.3. Geographical Revenue, 2019
16.8.4. Product Offerings
16.8.5. Recent Initiatives (2017-2019)
16.9. Takeda Pharmaceutical Company Limited
16.9.1. Company Snapshot
16.9.2. Company Overview
16.9.3. Financial Performance (2015-2019)
16.9.3.1. Net Revenue
16.9.3.2. Gross Profit
16.9.3.3. Geographical Revenue, 2019
16.9.4. Product Offerings
16.9.5. Recent Initiatives (2017-2019)
16.10. Endo International plc
16.10.1. Company Snapshot
16.10.2. Company Overview
16.10.3. Financial Performance (2015-2019)
16.10.3.1. Net Revenue
16.10.3.2. Gross Profit
16.10.3.3. Geographical Revenue, 2019
16.10.4. Product Offerings
16.10.5. Recent Initiatives (2017-2019)
16.11. Other Notable Players
17. Conclusion
18. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Neurological Disorder Drugs Market Drivers & Restraints 2021
Table 7. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 178. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 193. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 197. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 248. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 253. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 263. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 264. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 265. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 266. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 267. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 268. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 269. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 270. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 271. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 272. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 273. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 274. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 275. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 276. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 277. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 278. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 452. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 453. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 454. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 455. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 456. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 457. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 458. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 459. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 460. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 461. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 462. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 463. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 464. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 465. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 466. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 467. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 468. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 469. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 470. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 471. Leading 10 Neurological Disorder Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 472. Pfizer IncProfile 2019 (CEO, HQ, Founded, Website)
Table 473. Pfizer Inc Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 474. Eli Lilly and Company Profile 2019 (CEO, HQ, Founded, Website)
Table 475. Eli Lilly and Company Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 476. Novartis AG Profile 2019 (CEO, HQ, Founded, Website)
Table 477. Novartis AG.Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 478. F. Hoffmann-La Roche Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 479. F. Hoffmann-La Roche Ltd Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 480. Eisai Co., Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 481. Eisai Co., Ltd Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 482. Allergan Profile 2019 (CEO, HQ, Founded, Website)
Table 483. Allergan Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 484. Teva Pharmaceutical Industries Ltd Profile 2019 (CEO, HQ, Founded, Website)
Table 485. Teva Pharmaceutical Industries Ltd Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 486. Bristol-Myers Squibb Company Profile 2019 (CEO, HQ, Founded, Website)
Table 487. Bristol-Myers Squibb Company Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 488. Takeda Pharmaceutical Company Limited Profile 2019 (CEO, HQ, Founded, Website)
Table 489. Takeda Pharmaceutical Company Limited Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 490. Endo International plc Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 491. Endo International plc Neurological Disorder Drugs Product Offering (Segment, Product Offerings)
Table 492. Other Companies Involved in the Neurological Disorder Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Neurological Disorder Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Neurological Disorder Drugs Market Drivers & Restraints 2021
Figure 7. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. NMDA Receptor Antagonists Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Antipsychotic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Antidepressant Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Anticholinergic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Analgesic Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Hypnotic & Sedative Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Anticoagulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Antihypertensive Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Epilepsy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Alzheimer’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Parkinson’s Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Multiple Sclerosis Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Cerebrovascular Disease Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Academic and Research Institute Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 178. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 193. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Online Pharmacies Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. North America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. North America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. North America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. North America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. North America Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. US Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. Canada Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 248. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Europe Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 253. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 263. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 264. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 265. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 266. Europe Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 267. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 268. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 269. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 270. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 271. Europe Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 272. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 273. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 274. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 275. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 276. Europe Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 277. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 278. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 279. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 280. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 281. Europe Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 282. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Europe Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. UK Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. Germany Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. France Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Rest of Europe Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Asia Pacific Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Asia Pacific Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Asia Pacific Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Asia Pacific Neurological Disorder Drugs Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. China Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. India Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Japan Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. RoAPAC Neurological Disorder Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Middle East Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Middle East Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Middle East Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Middle East Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Middle East Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Latin America Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Latin America Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Latin America Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Latin America Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Latin America Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Africa Neurological Disorder Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Neurological Disorder Drugs Market Forecast By Disease Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Neurological Disorder Drugs Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 452. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 453. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 454. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 455. Africa Neurological Disorder Drugs Market Forecast By Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 456. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 457. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 458. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 459. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 460. Africa Neurological Disorder Drugs Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 461. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 462. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 463. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 464. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 465. Africa Neurological Disorder Drugs Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 466. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 467. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 468. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 469. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 470. Africa Neurological Disorder Drugs Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 471. Porter’s Five Force Analysis
Companies Mentioned
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
Companies Profiled in the Report
1. Pfizer Inc
2. Eli Lilly and Company
3. Novartis AG
4. F. Hoffmann-La Roche Ltd
5. Eisai Co., Ltd
6. Allergan
7. Teva Pharmaceutical Industries Ltd
8. Bristol-Myers Squibb Company
9. Takeda Pharmaceutical Company Limited
10. Endo International plc
List of Companies Mentioned in the Report:
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
1. Pfizer Inc
2. Eli Lilly and Company
3. Novartis AG
4. F. Hoffmann-La Roche Ltd
5. Eisai Co., Ltd
6. Allergan
7. Teva Pharmaceutical Industries Ltd
8. Bristol-Myers Squibb Company
9. Takeda Pharmaceutical Company Limited
10. Endo International plc
List of Companies Mentioned in the Report:
1. GlaxoSmithKline PLC
2. Biomarin Pharmaceutical Inc
3. Grifols SA
4. UCB SA
5. Eisai Co Ltd
6. Novo Nordisk A/S
7. Alexion Pharmaceuticals Inc
8. Takeda Pharmaceutical Co Ltd
9. Chugai Pharmaceutical Co Ltd
10. Perrigo Company PLC
11. Astellas Pharma Inc
12. Mitsubishi Tanabe Pharma Corp
13. Johnson & Johnson
14. Shanghai Fosun Pharmaceutical Group Co Ltd
15. Jiangsu Hengrui Medicine Co Ltd
16. Allergan plc
17. Shire PLC
18. Kyowa Hakko Kirin Co Ltd
19. Pfizer Inc
20. Taisho Pharmaceutical Holdings Co Ltd
21. MYL.O
22. Zoetis Inc
23. Bristol-Myers Squibb Co
24. Merck & Co Inc
25. AbbVie Inc
26. Jazz Pharmaceuticals PLC
27. Sumitomo Dainippon Pharma Co Ltd
28. AstraZeneca PLC
29. China Grand Automotive Services Co Ltd
30. Daiichi Sankyo Co Ltd
31. Novartis AG
32. Tasly Pharmaceutical Group Co Ltd
33. CSL Ltd
34. Biogen Inc
35. Orion Oyj
36. Bayer AG
37. CSPC Pharmaceutical Group Ltd
38. Sanofi SA
39. Roche Holding AG
40. Ono Pharmaceutical Co Ltd
41. Beijing Tongrentang Co Ltd
42. Kangmei Pharmaceutical Co Ltd
43. Ipsen SA
44. Abbott Laboratories
45. Shionogi & Co Ltd
46. Eli Lilly and Co
47. Recordati Industria Chimica e Farmaceutica SpA
48. Hikma Pharmaceuticals PLC
49. Teva Pharmaceutical Industries Ltd
50. Merck KGaA
List of Organizations Mentioned in the Report:
1. European Medicines Agency (EMA)
2. Food and Drug Administration (FDA)
3. National Institutes of Health (NIH)
4. United Nations (UN)
5. United Nations Office on Drugs and Crime (UNODC)
6. United Nations Statistics Division (UNSD)
7. Statistical Office of the European Union (EUROSTAT)
8. University of Connecticut
9. World Health Organization (WHO)
10. The National Medical Products Administration (NMPA)
11. Indian Council of Medical Research (ICMR)
12. The Therapeutic Goods Administration
13. The Federal Institute for Drugs and Medical Devices (BfArM)
14. Pharmaceuticals and Medical Devices Agency (PMDA)
15. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
16. Ministry of Health, Labour & Welfare(MHLW)
17. Medicines and Healthcare Products Regulatory Agency (MHRA)
18. Centre for Pharmaceutical Administration Health Sciences Authority
19. Central Drug Standard Control Organization (CDSCO)
20. Organisation for Economic Co-operation and Development (OECD)
Download sample pages
Complete the form below to download your free sample pages for Neurological Disorder Drugs Market Report 2021-2031Related reports
Acute Repetitive Seizures Market Report 2019-2029
On the basis of product, NRL-1 is expected to be the fastest-growing segment over the forecast period used for children,...
Full DetailsPublished: 01 January 1970Global Neurostimulation Devices Market 2019-2029
The global neurostimulation devices market will reach $13bn in 2024 and is estimated to grow at a CAGR of 13%...
Full DetailsPublished: 28 November 2018Epilepsy Therapeutics Market Report 2021-2031
As governments in emerging countries are taking measures to improve healthcare, it is positively impacting the anti-epileptic drugs market growth....Full DetailsPublished: 18 August 2021Deep Brain Stimulation Devices Market Report 2020-2030
Where is the Deep Brain Stimulation Devices market heading? If you are involved in this sector you must read this...
Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Neurological Disorder Drugs Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes eClinical Solutions Market Report 2023-2033
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
17 March 2023
Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
15 March 2023
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
10 March 2023
Visiongain Publishes Sleep Tech Market Report 2023-2033
The global Sleep Tech market was valued at US$16.08 billion in 2022 and is projected to grow at a CAGR of 22.6% during the forecast period 2023-2033.
03 March 2023
